{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T04:47:15Z","timestamp":1783745235672,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40123-026-01338-9","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T11:31:37Z","timestamp":1772019097000},"page":"1165-1177","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-World 6-Month Treatment Outcomes of Faricimab in Turkey: The FARTURK Study"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5880-283X","authenticated-orcid":false,"given":"Ak\u0131n","family":"\u00c7ak\u0131r","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fevzi","family":"Akkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziya","family":"Kapran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melih","family":"\u00dcnal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigar","family":"\u015eerif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahsin","family":"Uzundede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamze","family":"Karata\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmut","family":"\u00d6zt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00fcseyin","family":"D\u00fcndar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tansu","family":"Erakg\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Numan","family":"Alp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nil\u00fcfer","family":"Ko\u00e7ak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Osman","family":"Saatci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebru Nevin","family":"\u00c7etin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Hakan","family":"Durukan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzaffer","family":"\u015eahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fer\u015fat","family":"Muhacir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya\u011fmur Seda","family":"Ye\u015filta\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman Murat","family":"Uyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinan","family":"Emre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Ali","family":"\u015eekero\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"\u00d6nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Bulut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aylin","family":"Karalezli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibel","family":"Kaday\u0131f\u00e7\u0131lar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eeng\u00fcl","family":"\u00d6zdek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selim","family":"Do\u011fanay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmut","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zay","family":"\u00d6z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sema Tamer","family":"Kaderli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remzi","family":"Avc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Figen","family":"\u015eermet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibel","family":"Demirel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"K\u00fc\u00e7\u00fckerd\u00f6nmez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Y\u0131ld\u0131r\u0131m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eefik Can","family":"\u0130pek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziya","family":"Ayhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu\u011frul","family":"Altan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130hsan G\u00f6khan","family":"G\u00fcrelik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebru","family":"G\u00f6rg\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nursal Melda","family":"Yenerel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6ktu\u011f","family":"Seymeno\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra","family":"Vural","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabahattin","family":"S\u00fcl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"\u00c7\u0131t\u0131r\u0131k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00fcseyin Baran","family":"\u00d6zdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do\u011fukan","family":"C\u00f6merter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veysel Levent","family":"Karaba\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"\u00d6zdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"1338_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.preteyeres.2017.10.006","volume":"63","author":"A Daruich","year":"2018","unstructured":"Daruich A, Matet A, Moulin A, et al. Mechanisms of macular edema: beyond the surface. Prog Retin Eye Res. 2018;63:20\u201368.","journal-title":"Prog Retin Eye Res"},{"issue":"10","key":"1338_CR2","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1097\/IAE.0000000000001158","volume":"36","author":"RF Spaide","year":"2016","unstructured":"Spaide RF. RETINAL VASCULAR CYSTOID MACULAR EDEMA: review and new theory. Retina. 2016;36(10):1823\u201342. https:\/\/doi.org\/10.1097\/IAE.0000000000001158.","journal-title":"Retina"},{"key":"1338_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.preteyeres.2015.06.002","volume":"49","author":"PA Campochiaro","year":"2015","unstructured":"Campochiaro PA. Molecular pathogenesis of retinal and choroidal vascular diseases. Prog Retin Eye Res. 2015;49:67\u201381.","journal-title":"Prog Retin Eye Res"},{"key":"1338_CR4","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(22)00010-1.","journal-title":"Lancet"},{"key":"1338_CR5","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.2147\/OPTH.S489114","volume":"18","author":"LS Aldokhail","year":"2024","unstructured":"Aldokhail LS, Alhadlaq AM, Alaradi LM, et al. Outcomes of anti-VEGF therapy in eyes with diabetic macular edema, vein occlusion-related macular edema, and neovascular age-related macular degeneration: a systematic review. Clin Ophthalmol. 2024;18:3837\u201351.","journal-title":"Clin Ophthalmol"},{"key":"1338_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.10.016","author":"SB Bloch","year":"2012","unstructured":"Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in Denmark: Year 2000 to 2010. Am J Ophthalmol. 2012. https:\/\/doi.org\/10.1016\/j.ajo.2011.10.016.","journal-title":"Am J Ophthalmol"},{"key":"1338_CR7","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","volume":"37","author":"AM Khanani","year":"2023","unstructured":"Khanani AM, Aziz AA, Khan H, et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study\u20146 month results. Eye (Basingstoke). 2023;37:3574\u201381. https:\/\/doi.org\/10.1038\/s41433-023-02553-5.","journal-title":"Eye (Basingstoke)"},{"key":"1338_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/life14020193","author":"B Ng","year":"2024","unstructured":"Ng B, Kolli H, Ajith Kumar N, et al. Real-world data on faricimab switching in treatment-refractory neovascular age-related macular degeneration. Life. 2024. https:\/\/doi.org\/10.3390\/life14020193.","journal-title":"Life"},{"key":"1338_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-024-00525-9","author":"FM Penha","year":"2024","unstructured":"Penha FM, Masud M, Khanani ZA, et al. Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME. Int J Retina Vitreous. 2024. https:\/\/doi.org\/10.1186\/s40942-024-00525-9.","journal-title":"Int J Retina Vitreous"},{"key":"1338_CR10","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","volume":"399","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399:741\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(22)00018-6.","journal-title":"Lancet"},{"key":"1338_CR11","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1038\/s41433-024-03223-w","volume":"38","author":"L Downey","year":"2024","unstructured":"Downey L, Sivaprasad S, Chhabra R, et al. Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialists. Eye. 2024;38:3077\u201386. https:\/\/doi.org\/10.1038\/s41433-024-03223-w.","journal-title":"Eye"},{"key":"1338_CR12","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","volume":"131","author":"TY Wong","year":"2024","unstructured":"Wong TY, Haskova Z, Asik K, et al. Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase 3 YOSEMITE and RHINE trials. Ophthalmology. 2024;131:708\u201323. https:\/\/doi.org\/10.1016\/j.ophtha.2023.12.026.","journal-title":"Ophthalmology"},{"key":"1338_CR13","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, et al. TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2. Ophthalmology. 2024;131:914\u201326. https:\/\/doi.org\/10.1016\/j.ophtha.2024.02.014.","journal-title":"Ophthalmology"},{"key":"1338_CR14","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s40123-024-00920-3","volume":"13","author":"MA Zarbin","year":"2024","unstructured":"Zarbin MA, MacCumber MW, Karcher H, et al. Real-world safety outcomes with brolucizumab in neovascular age-related macular degeneration: findings from the IRIS\u00ae registry. Ophthalmol Ther. 2024;13:1357\u201368. https:\/\/doi.org\/10.1007\/s40123-024-00920-3.","journal-title":"Ophthalmol Ther"},{"key":"1338_CR15","unstructured":"Wykoff CC, Matsumoto H, Barakat MR, et al. Review retinal vasculitis or vascular occlusion after olokizumab for neovascular age-related macular degeneration a systematic review of real-world evidence"},{"key":"1338_CR16","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1080\/02713683.2021.1908566","volume":"46","author":"K Xiong","year":"2021","unstructured":"Xiong K, Gong X, Li W, et al. Comparison of macular thickness measurements using swept-source and spectral-domain optical coherence tomography in healthy and diabetic subjects. Curr Eye Res. 2021;46:1567\u201373. https:\/\/doi.org\/10.1080\/02713683.2021.1908566.","journal-title":"Curr Eye Res"},{"key":"1338_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2010.06.025","author":"A Giani","year":"2010","unstructured":"Giani A, Cigada M, Choudhry N, et al. Reproducibility of retinal thickness measurements on normal and pathologic eyes by different optical coherence tomography instruments. Am J Ophthalmol. 2010. https:\/\/doi.org\/10.1016\/j.ajo.2010.06.025.","journal-title":"Am J Ophthalmol"},{"key":"1338_CR18","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","volume":"123","author":"JA Wells","year":"2016","unstructured":"Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123:1351\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2016.02.022.","journal-title":"Ophthalmology"},{"key":"1338_CR19","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.oret.2025.01.017","volume":"9","author":"JI Lim","year":"2025","unstructured":"Lim JI, Amador MJ, Dhoot DS, et al. Anatomic control with faricimab versus aflibercept in the YOSEMITE\/RHINE trials in diabetic macular edema. Ophthalmol Retina. 2025;9:655\u201366. https:\/\/doi.org\/10.1016\/j.oret.2025.01.017.","journal-title":"Ophthalmol Retina"},{"key":"1338_CR20","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ophtha.2024.11.023","volume":"132","author":"CMG Cheung","year":"2025","unstructured":"Cheung CMG, Lim JI, Priglinger S, et al. Anatomic outcomes with faricimab vs aflibercept in head-to-head dosing phase of the TENAYA\/LUCERNE trials in neovascular age-related macular degeneration. Ophthalmology. 2025;132:519\u201326. https:\/\/doi.org\/10.1016\/j.ophtha.2024.11.023.","journal-title":"Ophthalmology"},{"key":"1338_CR21","doi-asserted-by":"publisher","first-page":"e260","DOI":"10.1111\/aos.14572","volume":"99","author":"AM Haas","year":"2021","unstructured":"Haas AM, Ahmed D, Stattin M, et al. Comparison of macular neovascularization lesion size by the use of spectral-domain optical coherence tomography angiography and swept-source optical coherence tomography angiography versus indocyanine green angiography. Acta Ophthalmol. 2021;99:e260\u20136. https:\/\/doi.org\/10.1111\/aos.14572.","journal-title":"Acta Ophthalmol"},{"key":"1338_CR22","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.2147\/OPTH.S549586","volume":"19","author":"S Chujo","year":"2025","unstructured":"Chujo S, Matsubara H, Mase Y, et al. Comparisons of early changes of vascular structure after treatment with faricimab and aflibercept in eyes with macular neovascularization by OCT angiography. Clin Ophthalmol. 2025;19:3527\u201333. https:\/\/doi.org\/10.2147\/OPTH.S549586.","journal-title":"Clin Ophthalmol"},{"key":"1338_CR23","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.11.9.18","author":"P Viggiano","year":"2022","unstructured":"Viggiano P, Grassi MO, Pignataro M, et al. Topographical analysis of the choriocapillaris reperfusion after loading anti-VEGF therapy in neovascular AMD. Transl Vis Sci Technol. 2022. https:\/\/doi.org\/10.1167\/tvst.11.9.18.","journal-title":"Transl Vis Sci Technol"},{"key":"1338_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13175042","author":"H Faatz","year":"2024","unstructured":"Faatz H, Lommatzsch A. Overview of the use of optical coherence tomography angiography in neovascular age-related macular degeneration. J Clin Med. 2024. https:\/\/doi.org\/10.3390\/jcm13175042.","journal-title":"J Clin Med"},{"key":"1338_CR25","doi-asserted-by":"publisher","first-page":"OCT307","DOI":"10.1167\/iovs.15-18830","volume":"57","author":"E Costanzo","year":"2016","unstructured":"Costanzo E, Miere A, Querques G, et al. Type 1 choroidal neovascularization lesion size: indocyanine green angiography versus optical coherence tomography angiography. Invest Ophthalmol Vis Sci. 2016;57:OCT307\u201313. https:\/\/doi.org\/10.1167\/iovs.15-18830.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1338_CR26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/IAE.0000000000004635","volume":"46","author":"MM Carl\u00e0","year":"2026","unstructured":"Carl\u00e0 MM, Scampoli A, Grieco G, et al. Morphometric changes in macular neovascularization architecture after faricimab treatment in neovascular age-related macular degeneration. Retina. 2026;46:125\u201335. https:\/\/doi.org\/10.1097\/IAE.0000000000004635.","journal-title":"Retina"},{"key":"1338_CR27","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.2147\/OPTH.S547179","volume":"19","author":"Y Mizuki","year":"2025","unstructured":"Mizuki Y, Inokuchi S, Kuroki T, et al. Two-year real-world outcomes of faricimab for diabetic macular edema in Japan. Clin Ophthalmol. 2025;19:3051\u20138. https:\/\/doi.org\/10.2147\/OPTH.S547179.","journal-title":"Clin Ophthalmol"},{"key":"1338_CR28","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41433-023-02505-z","volume":"37","author":"PE Stanga","year":"2023","unstructured":"Stanga PE, Valent\u00edn-Bravo FJ, Stanga SEF, et al. Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic. Eye (Basingstoke). 2023;37:3282\u20139. https:\/\/doi.org\/10.1038\/s41433-023-02505-z.","journal-title":"Eye (Basingstoke)"}],"updated-by":[{"DOI":"10.1007\/s40123-026-01369-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000}}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01338-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01338-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01338-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T07:26:39Z","timestamp":1775287599000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01338-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1338"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01338-9","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"30 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised due to given name of the author Ya\u011fmur Seda Ye\u015filta\u015f was incorrectly published as Seda Ye\u015filta\u015f. Now, the author name has been corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40123-026-01369-2","URL":"https:\/\/doi.org\/10.1007\/s40123-026-01369-2","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ak\u0131n \u00c7ak\u0131r, Fevzi Akkan, Ziya Kapran, Melih \u00dcnal, Nigar \u015eerif, Tahsin Uzundede, Gamze Karata\u015f, Mahmut \u00d6zt\u00fcrk, H\u00fcseyin D\u00fcndar, Tansu Erakg\u00fcn, Mehmet Numan Alp, Nil\u00fcfer Ko\u00e7ak, Ali Osman Saatci, Ebru Nevin \u00c7etin, Ali Hakan Durukan, Muzaffer \u015eahin, Fer\u015fat Muhacir, Ya\u011fmur Seda Ye\u015filta\u015f, Osman Murat Uyar, Sinan Emre, Mehmet Ali \u015eekero\u011flu, Mehmet \u00d6nen, Mehmet Bulut, Aylin Karalezli, Sibel Kaday\u0131f\u00e7\u0131lar, \u015eeng\u00fcl \u00d6zdek, Selim Do\u011fanay, Mahmut Kaya, \u00d6zay \u00d6z, Sema Tamer Kaderli, Remzi Avc\u0131, Figen \u015eermet, Sibel Demirel, Cem K\u00fc\u00e7\u00fckerd\u00f6nmez, Cem Y\u0131ld\u0131r\u0131m, \u015eefik Can \u0130pek, Ziya Ayhan, Tu\u011frul Altan, \u0130hsan G\u00f6khan G\u00fcrelik, Ebru G\u00f6rg\u00fcn, Nursal Melda Yenerel, G\u00f6ktu\u011f Seymeno\u011flu, Esra Vural, Sabahattin S\u00fcl, Mehmet \u00c7\u0131t\u0131r\u0131k, H\u00fcseyin Baran \u00d6zdemir, Do\u011fukan C\u00f6merter, Veysel Levent Karaba\u015f and Hakan \u00d6zdemir have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval for this retrospective, multicenter, observational clinical study was obtained from the Bezmialem Vak\u0131f University Ethics Committee (Approval ID: E-54022451-050.04-206890). The study was conducted in accordance with the principles of the Declaration of Helsinki (1964) and its subsequent amendments. Informed consent to participate was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}